FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382933408> ?p ?o ?g. }

• W4382933408 endingPage "554" @default.
• W4382933408 startingPage "545" @default.
• W4382933408 abstract "Background Transcranial direct current stimulation (tDCS) has been proposed as a feasible treatment for major depressive disorder (MDD). However, meta-analytic evidence is heterogenous and data from multicentre trials are scarce. We aimed to assess the efficacy of tDCS versus sham stimulation as an additional treatment to a stable dose of selective serotonin reuptake inhibitors (SSRIs) in adults with MDD. Methods The DepressionDC trial was triple-blind, randomised, and sham-controlled and conducted at eight hospitals in Germany. Patients being treated at a participating hospital aged 18–65 years were eligible if they had a diagnosis of MDD, a score of at least 15 on the Hamilton Depression Rating Scale (21-item version), no response to at least one antidepressant trial in their current depressive episode, and treatment with an SSRI at a stable dose for at least 4 weeks before inclusion; the SSRI was continued at the same dose during stimulation. Patients were allocated (1:1) by fixed-blocked randomisation to receive either 30 min of 2 mA bifrontal tDCS every weekday for 4 weeks, then two tDCS sessions per week for 2 weeks, or sham stimulation at the same intervals. Randomisation was stratified by site and baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score (ie, <31 or ≥31). Participants, raters, and operators were masked to treatment assignment. The primary outcome was change on the MADRS at week 6, analysed in the intention-to-treat population. Safety was assessed in all patients who received at least one treatment session. The trial was registered with ClinicalTrials.gov (NCT02530164). Findings Between Jan 19, 2016, and June 15, 2020, 3601 individuals were assessed for eligibility. 160 patients were included and randomly assigned to receive either active tDCS (n=83) or sham tDCS (n=77). Six patients withdrew consent and four patients were found to have been wrongly included, so data from 150 patients were analysed (89 [59%] were female and 61 [41%] were male). No intergroup difference was found in mean improvement on the MADRS at week 6 between the active tDCS group (n=77; –8·2, SD 7·2) and the sham tDCS group (n=73; –8·0, 9·3; difference 0·3 [95% CI –2·4 to 2·9]). Significantly more participants had one or more mild adverse events in the active tDCS group (50 [60%] of 83) than in the sham tDCS group (33 [43%] of 77; p=0·028). Interpretation Active tDCS was not superior to sham stimulation during a 6-week period. Our trial does not support the efficacy of tDCS as an additional treatment to SSRIs in adults with MDD. Funding German Federal Ministry of Education and Research." @default.
• W4382933408 created "2023-07-04" @default.
• W4382933408 creator A5005246279 @default.
• W4382933408 creator A5009082696 @default.
• W4382933408 creator A5009196227 @default.
• W4382933408 creator A5009655648 @default.
• W4382933408 creator A5014532124 @default.
• W4382933408 creator A5016192642 @default.
• W4382933408 creator A5016354042 @default.
• W4382933408 creator A5018278195 @default.
• W4382933408 creator A5021871026 @default.
• W4382933408 creator A5033587887 @default.
• W4382933408 creator A5035336709 @default.
• W4382933408 creator A5044546802 @default.
• W4382933408 creator A5045775030 @default.
• W4382933408 creator A5045833650 @default.
• W4382933408 creator A5047580809 @default.
• W4382933408 creator A5047724015 @default.
• W4382933408 creator A5049566959 @default.
• W4382933408 creator A5050095696 @default.
• W4382933408 creator A5052305997 @default.
• W4382933408 creator A5054861340 @default.
• W4382933408 creator A5056684559 @default.
• W4382933408 creator A5057302175 @default.
• W4382933408 creator A5058622453 @default.
• W4382933408 creator A5061069993 @default.
• W4382933408 creator A5063506824 @default.
• W4382933408 creator A5064104774 @default.
• W4382933408 creator A5070078265 @default.
• W4382933408 creator A5071728849 @default.
• W4382933408 creator A5073876020 @default.
• W4382933408 creator A5073959986 @default.
• W4382933408 creator A5075820157 @default.
• W4382933408 creator A5081203934 @default.
• W4382933408 date "2023-08-01" @default.
• W4382933408 modified "2023-10-07" @default.
• W4382933408 title "Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham-controlled, multicentre trial" @default.
• W4382933408 cites W1964027379 @default.
• W4382933408 cites W2015658985 @default.
• W4382933408 cites W2023687307 @default.
• W4382933408 cites W2062103870 @default.
• W4382933408 cites W2069138677 @default.
• W4382933408 cites W2080398576 @default.
• W4382933408 cites W2109163290 @default.
• W4382933408 cites W2114613490 @default.
• W4382933408 cites W2131823335 @default.
• W4382933408 cites W2132324173 @default.
• W4382933408 cites W2148765295 @default.
• W4382933408 cites W2169624269 @default.
• W4382933408 cites W2408786560 @default.
• W4382933408 cites W2531210989 @default.
• W4382933408 cites W2594889620 @default.
• W4382933408 cites W2686038515 @default.
• W4382933408 cites W2732204853 @default.
• W4382933408 cites W2765509638 @default.
• W4382933408 cites W289615364 @default.
• W4382933408 cites W2996510667 @default.
• W4382933408 cites W3008639106 @default.
• W4382933408 cites W3194244082 @default.
• W4382933408 cites W4220884311 @default.
• W4382933408 cites W4224253262 @default.
• W4382933408 doi "https://doi.org/10.1016/s0140-6736(23)00640-2" @default.
• W4382933408 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37414064" @default.
• W4382933408 hasPublicationYear "2023" @default.
• W4382933408 type Work @default.
• W4382933408 citedByCount "4" @default.
• W4382933408 countsByYear W43829334082023 @default.
• W4382933408 crossrefType "journal-article" @default.
• W4382933408 hasAuthorship W4382933408A5005246279 @default.
• W4382933408 hasAuthorship W4382933408A5009082696 @default.
• W4382933408 hasAuthorship W4382933408A5009196227 @default.
• W4382933408 hasAuthorship W4382933408A5009655648 @default.
• W4382933408 hasAuthorship W4382933408A5014532124 @default.
• W4382933408 hasAuthorship W4382933408A5016192642 @default.
• W4382933408 hasAuthorship W4382933408A5016354042 @default.
• W4382933408 hasAuthorship W4382933408A5018278195 @default.
• W4382933408 hasAuthorship W4382933408A5021871026 @default.
• W4382933408 hasAuthorship W4382933408A5033587887 @default.
• W4382933408 hasAuthorship W4382933408A5035336709 @default.
• W4382933408 hasAuthorship W4382933408A5044546802 @default.
• W4382933408 hasAuthorship W4382933408A5045775030 @default.
• W4382933408 hasAuthorship W4382933408A5045833650 @default.
• W4382933408 hasAuthorship W4382933408A5047580809 @default.
• W4382933408 hasAuthorship W4382933408A5047724015 @default.
• W4382933408 hasAuthorship W4382933408A5049566959 @default.
• W4382933408 hasAuthorship W4382933408A5050095696 @default.
• W4382933408 hasAuthorship W4382933408A5052305997 @default.
• W4382933408 hasAuthorship W4382933408A5054861340 @default.
• W4382933408 hasAuthorship W4382933408A5056684559 @default.
• W4382933408 hasAuthorship W4382933408A5057302175 @default.
• W4382933408 hasAuthorship W4382933408A5058622453 @default.
• W4382933408 hasAuthorship W4382933408A5061069993 @default.
• W4382933408 hasAuthorship W4382933408A5063506824 @default.
• W4382933408 hasAuthorship W4382933408A5064104774 @default.
• W4382933408 hasAuthorship W4382933408A5070078265 @default.
• W4382933408 hasAuthorship W4382933408A5071728849 @default.
• W4382933408 hasAuthorship W4382933408A5073876020 @default.
• W4382933408 hasAuthorship W4382933408A5073959986 @default.

• next